Publications by authors named "S F Erdes"
Background: Modern elite football places extremely high demands on the athlete's body, so it is of practical interest to study the effect of various dietary supplements on load tolerance and postexercise recovery. Furthermore, there is a lack of research on the effects of caffeine on key measures of load tolerance in football such as delayed-onset muscle soreness (DOMS), rate of perceived exertion (RPE) and heart rate (HR) at different time points after the exercise.
Methods: 54 young players aged 15-17 years from a leading Russian football academy took part in a randomised trial using the balanced placebo design.
Article Synopsis
- Netakimab has shown effective results in controlled trials for treating ankylosing spondylitis (AS), and this study investigates its efficacy and safety in everyday clinical settings over a year.
- The observational study included 137 patients from 23 centers in Russia, focusing on retention rates and the impact of netakimab therapy at multiple time points during the year.
- Findings revealed that 90.4% of patients continued treatment after one year, and significant improvements were observed in disease activity scores, with only a small percentage experiencing adverse effects.
Aim: The hip joint is the most commonly affected non-axial joint in ankylosing spondylitis (AS). Data on the effects of tumor necrosis factor-α inhibitors (TNFi) in AS patients with coxitis are limited. The aim of this study was evaluation of coxitis treated with the TNFi golimumab in real-world settings.
View Article and Find Full Text PDFSpondyloarthritis (SpA) comprises a number of inflammatory rheumatic diseases with overlapping clinical manifestations. Strong association with several HLA-I alleles and T cell infiltration into an inflamed joint suggest involvement of T cells in SpA pathogenesis. In this study, we performed high-throughput T cell repertoire profiling of synovial fluid (SF) and peripheral blood (PB) samples collected from a large cohort of SpA patients.
View Article and Find Full Text PDFBackground: According to the treat-to-target strategy for spondyloarthritis (SpA), the main goal is to achieve clinical remission or inactive disease. In 2001, the Assessment of Spondyloarhtritis International Society (ASAS) formulated the ASAS criteria for partial remission, and the Russian expert group for the study of SpA identified clinical-laboratory remission (no clinical manifestations of the disease that persists for 6 months in the presence of normal values of C-reactive protein and erythrocyte sedimentation rate), magnetic resonance imaging (MRI) remission and complete remission (a combination of clinical-laboratory and MRI remission).
Aim: To determine the frequency of achieving clinical-laboratory and ASAS partial remission in patients with early axial SpA (axSpA) at the 3rd year of follow-up.